CAT 248
Alternative Names: CAT-248Latest Information Update: 05 Oct 2023
At a glance
- Originator Catamaran Bio
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Renal cell carcinoma; Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumours in USA (Parenteral) prior to May 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical phase in Renal cell carcinoma presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 11 Apr 2023 Catamaran Bio plans a clinical trial for Solid tumours in 2024